Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab

Autoimmunity Reviews

Volumn 12, Issue 11, 2013, Pages 1085-1090

  Berman, Horacio ^a   Rodríguez Pintó, Ignasi ^a   Cervera, Ricard ^a   Morel, Nathalie ^b,e   Costedoat Chalumeau, Nathalie ^b,e   Erkan, Doruk ^c   Shoenfeld, Yehuda ^d   Espinosa, Gerard ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

^e Institut Cochin   (France)

Author keywords

Anti CD20; Catastrophic antiphospholipid syndrome; Refractory; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; RITUXIMAB;

ADULT; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; CLINICAL FEATURE; FOLLOW UP; HUMAN; LABORATORY TEST; PLASMAPHERESIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTI-CD20; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; REFRACTORY; RITUXIMAB;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIPHOSPHOLIPID SYNDROME; CATASTROPHIC ILLNESS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PLASMA EXCHANGE; PLASMAPHERESIS; REGISTRIES; THROMBOSIS;

EID: 84881551069     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.05.004     Document Type: Review

References (26)

1. Branch D.W., Breyl R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4(2):295-306.
2. Erkan D., Espinosa G., Cervera R. Catastrophic antiphospholipid syndrome. Updated diagnostic algorithms. Autoimmun Rev 2010, 10(2):74-79.
3. Espinosa G., Cervera R., Asherson R.A. Catastrophic antiphospholipid syndrome and sepsis. A common link?. J Rheumatol 2007, 34(5):923-926.
4. Erkan D., Boffa M.C., Piette J.C., et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003, 12(7):530-534.
5. Gómez-Puerta J.A., Ramos-Casals M., Font J. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006, 54(8):2568-2576.
6. Espinosa G., Berman H., Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011, 10:664-668.
7. Burmester G., Dorner T., Ferraccioli G., et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70(6):909-920.
8. Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62(1):222-233.
9. Looney R.J., Fervenza F.C., Sanchez-Guerrero C., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. The lupus nephritis assessment with rituximab study. Arthritis Rheum 2012, 64(4):1215-1226.
10. Ramos-Casals M., Soto M.J., Cuadrado M.J., Khamashta M.A. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009, 18(9):767-776.
11. Erkan D., Vega J., Ramon G., Kozora E., Lockshin M.D. A pilot open label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 2013, 65(2):464-471.
12. Erre G.L., Pardini S., Faedda R., Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008, 17(1):50-55.
13. Shinada S., Ehresmann S., Liebman H.A. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006, 33(2):355-357.
14. Yinh J., Bucciarelli S., Bosch X., et al. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum 2008, 37(6):366-372.
15. Hackenberg U., Plum N., Josten K.M., et al. Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine. Am J Med Sci 2008, 335(5):394-397.
16. van den Dool E.J., Idu M.M., Levi M., et al. Catastrophic antiphospholipid syndrome mimicking a malignant pancreatic tumour - a case report. Lupus 2008, 17(6):586-590.
17. Nageswara Rao A.A., Arteaga G.M., Reed A.M., Gloor J.M., Rodriguez V. Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer 2009, 52(4):536-538.
18. Kochbati S., Mir K., Ben Ali Z., et al. Catastrophic antiphospholipid syndrome and rituximab: a new report. Tunis Med 2009, 87(10):699-702.
19. Iglesias-Jiménez E., Camacho-Lovillo M., Falcón-Neyra D., Lirola-Cruz J., Neth O. Infant with probable catastrophic antiphospholipid syndrome successfully managed with rituximab. Pediatrics 2010, 125(6):e1523-e1528.
20. Maliakkal J., Hoang V., Abdellatif A. Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy. Rheumatol Int 2010, 30(6):719-723.
21. Schonfeld T., Nahum E., Ling G., et al. Severe abdominal pain as a presenting symptom of probable catastrophic antiphospholipid syndrome. Pediatrics 2012, 130(1):e230-e235.
22. Camacho-Lovillo S., Bernabeu-Wittel J., Iglesias-Jimenez E., Falcon-Neyra D. Recurrence of cutaneous necrosis in an infant with probable catastrophic antiphospholipid syndrome. Pediatr Dermatol Sep 7 2012, 10.1111/j.1525-1470.2012.01832.x.
23. Leandro M.J., Migone T.S., Teodorescu M., et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008, 67(7):1011-1016.
24. Youinou P., Renaudineau Y. The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases. Thromb Res 2004, 114(5-6):363-369.
25. Leandro M.J., Edwards J.C., Isenberg D.A. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis 2008, 67(3):425-426.
26. Faillace C., De Carvalho J.F. Antiphospholipid syndrome development after rituximab treatment. Joint Bone Spine 2012, 79(2):200-201.